Appl. No. 10/028,726 Amdt. dated November 17, 2003 Reply to Office Action of October 16, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Please cancel claims 1-48 and add new claims 49-56.

1-48. (Canceled).

- 49. (New) A method of treating mammalian cancer cells lacking endogenous wild-type RB protein, which comprises introducing a wild-type RB tumor suppressing gene encoding said endogenous wild-type RB protein into said mammalian cancer cells, whereby said mammalian cancer cells' neoplastic phenotype is suppressed.
- 50. (New) A method of treating mammalian cancer cells lacking endogenous wild-type RB protein comprising introducing into said mammalian cancer cells wild-type RB tumor suppressor gene derived from the same mammalian species as said mammalian cells, whereby said mammalian cells' neoplastic phenotype is suppressed.
- 51. (New) A method of claim 49, wherein the mammalian cancer cells having no endogenous wild-type RB protein lacks the wild-type RB suppressor gene.
- 52. (New) A method of claim 50, wherein the mammalian cancer cells having no endogenous wild-type RB protein lacks the wild-type RB suppressor gene.
- 53. (New) A method of claim 49, wherein the introduction of the wild-type RB tumor suppressor gene is by retroviral infection.
- 54. (New) A method of claim 50, wherein the introduction of the wild-type RB tumor suppressor gene is by retroviral infection.

PATENT

Appl. No. 10/028,726 Amdt. dated November 17, 2003

Reply to Office Action of October 16, 2003

55. (New) A method of claim 49, wherein the mammalian cancer cell is an osteosarcoma cell, retinoblastoma cell, fibrosarcoma cell, glioblastoma cell, neuroblastoma cell or breast carcinoma cell.

56. (New) A method of claim 50, wherein the mammalian cancer cell is an osteosarcoma cell, retinoblastoma cell, fibrosarcoma cell, glioblastoma cell, neuroblastoma cell or breast carcinoma cell.